The size of the renal biomarkers market in North America is estimated to reach USD 545.75 Million by 2028 from USD 394.43 Million in 2023 and is forecasted to grow at a CAGR of 6.71% during the forecast period 2023 to 2028.
Y-O-Y growth in the indigence of chronic diseases and rising geriatric population in the North American countries are majorly anticipating the development of the market. Around 26.7 million or 11.5% of the U.S. adults are diagnosed with heart diseases due to the increasing occurrence of advanced kidney diseases and obstacles in 2014, According to CDC (Centers for Disease Control and Prevention). Along with the aging population, pediatric also suffer from renal diseases. Assistance from the government with funds and investments is boosting the market growth.
The appearance of leading renal biomarker manufacturers and established distribution channels are considered essential growth opportunities in the region. Nearly 26 million Americans are affected by chronic kidney diseases. In 2015, according to the National Kidney Foundation, around 468,000 end-stage renal disease patients were on dialysis in the U.S. Moreover, alcohol and tobacco consumption, obesity, and genetic and hereditary factors lead to an increase in the count of patients suffering from kidney diseases.
Low reimbursement concerns are one of the factors restraining the growth of renal biomarkers. Low sensitivity and specificity of biomarkers are predicted to impede the market. High cost for treatment where common people cannot afford is slowly hindering the demand of the market.
This research report on the North America Renal Biomarkers Market has been segmented and sub-segmented into the following categories:
By Diagnostic Technique:
The North American market held for a market share of 32% in the global renal biomarkers market in 2019. Factors like increasing population growth with kidney problems and a rise in renal diseases' occurrence rate are fueling the renal biomarkers market. Growing common diseases like high blood pressure and diabetes also boost the market growth.
The United States is anticipated to hold the largest share in the market due to growth in the number of US FDA approved drug labels comprising information on molecular biomarkers in the market. A vast growing aging population and an expected rise in co-morbidities, stimulating funds, and investments in research and development drive the renal biomarkers globally. Extensive renal biomarkers in clinical and pre-clinical trials to estimate drugs' safety and advancements in technology boost growth.
Canada is just behind the U.S and is expected to showcase fast growth in the region. New product inventions and the existence of launching new technologies at a reasonable price are stimulating market growth.
Promising Companies dominating the North America Renal Biomarkers Market Profiled in the Report are Abbott Diagnostics, F. Hoffmann-La Roche AG, Beckman Coulter Inc., Astute Medical Inc., Siemens Healthcare Diagnostics Inc., Thermo Fisher Scientific Inc., Alere Inc., bioMérieux SA, and Randox Laboratories Ltd.,
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com